AP - Beefed up oversight of the safety of drugs is in, but generic biotech drugs are out for now as the Senate began debate Monday on renewing fees paid by the pharmaceutical companies seeking approval for new medicines.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.